Demission of COO Lonza Group Ltd. Bioscience

Basel, Switzerland, 31 March 2010 – Anja Fiedler, COO Lonza Bioscience and member of the Management Committee of Lonza, has decided to resign from her functions due to health reasons. Lonza respects her decision and regrets to see her leaving the company.

Anja Fiedler joined Lonza in April 2009 to lead the Lonza Bioscience division. During her assignment the strategy and organization of Lonza Bioscience have been redesigned to continuously support the future growth opportunities.

Until a new candidate has been identified, Anja Fiedler will continue to stay in her position. The Board of Directors, the Management Committee and the staff of Lonza would like to thank Anja Fiedler for her excellent commitmentand wish her all the best.

About Lonza

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2009, Lonza had sales of CHF 2.690 billion. Further information can be found at www.lonza.com.